Wednesday 18 November 2026Search
World

FDA approves first drug for Type 3 Gaucher disease neurological symptoms

2 min read

The U.S. Food and Drug Administration approved Infilbray (venglustat) tablets for neurological symptoms of Type 3 Gaucher disease in adults and pediatric patients weighing at least 15 kg (approximately 33 pounds). The announcement was published Wednesday 18 November 2026. The approval made Infilbray the first treatment for those symptoms.

Infilbray crosses the blood-brain barrier to reduce the accumulation of harmful substances in the body and brain. Acting FDA Commissioner Kyle Diamantas, J.D. said the ability to cross the blood-brain barrier allows the drug to reach the source of buildup driving neurological symptoms. He said the approval brought an important new treatment to patients with rare diseases and healthcare providers who care for them.

Type 3 Gaucher disease is a rare, inherited condition in which the body cannot properly break down fatty substances because of a deficient or malfunctioning enzyme. The disease affects organs, tissues and the brain. It can cause difficulties with balance, coordination, speech, memory and thinking. These symptoms can worsen over time.

The FDA said its approval of Infilbray was supported by a randomized, double-blind, multicenter clinical study. The study enrolled 43 patients aged 12 years and older with Type 3 Gaucher disease who had received enzyme replacement therapy and achieved systemic disease stabilization. Participants received Infilbray orally once daily or intravenous enzyme replacement therapy every two weeks for 52 weeks.

Treatment effectiveness was evaluated with two assessments covering neurological symptoms, including ataxia and cognitive function. At Week 52, patients treated with Infilbray showed improvement on a measure combining the assessments compared with patients taking enzyme replacement therapy for non-neurologic manifestations of the disease.

The most frequently reported side effects included gastrointestinal symptoms and adverse effects on mood. Serious psychiatric risks, including suicidal ideation and behavior, have been reported. Animal studies identified potential clouding of vision in younger patients and adverse effects on fetal development during pregnancy. Infilbray received Orphan Drug designation and Priority Review. The approval was granted to Genzyme Corporation, a Sanofi Company.